Enzalutamide is a pharmaceutical drug used to treat prostate most cancers. In a big clinical trial known as EMBARK, researchers observed that enzalutamide improved metastasis-free survival in sufferers with non-metastatic castration-touchy prostate cancer with biochemical recurrence at excessive threat for metastasis.
The FDA has permitted enzalutamide (Xtandi) for nmCSPC with biochemical recurrence at excessive hazard for metastasis, based at the outcomes of the EMBARK trial. The approval is for treatment with enzalutamide 160 mg as soon as each day plus leuprolide, or enzalutamide one hundred sixty mg once daily as a unmarried agent.
https://www.chawlamedicos.com/anticancer/enzalutamide-40-mg-tablets
